DALLAS, June 26, 2012 /PRNewswire/ -- Goldfarb LLP
is investigating whether the board of directors of Aeterna
Zentaris, Inc. (NASDAQ: AEZS) violated shareholder protection laws
for issuing materially false and misleading statements to investors
that artificially inflated the company's stock price. Concerned
Aeterna Zentaris investors are encouraged to contact attorney
Hamilton Lindley at 877-583-2855 or hlindley@goldfarbllp.com about
their rights and remedies.
"On April 2, 2012, the company
announced that its development-stage colon cancer drug, perifosine,
failed to improve overall survival in patients in testing,"
securities lawyer Hamilton Lindley said. "As a result, shares have
fallen from $2.14 per share on
March 30 to $0.73 per share on April
2, losing approximately 66% of their value. Our proposed
shareholder lawsuit will seek to ensure that proper controls are
placed to ensure accurate financial reporting, to correct any
improper behavior, and to improve the company's value for
investors."
Goldfarb LLP lawyers have significant experience representing
shareholders and whistleblowers in securities lawsuits nationwide.
Aeterna Zentaris, Inc. shareholders – or anyone with knowledge
about this situation – should contact lawyer Hamilton Lindley
at
hlindley@goldfarbllp.com or 877-583-2855.
Hamilton Lindley
Goldfarb LLP
2501 N. Harwood, Ste. 1801
Dallas, TX 75201
(877) 583-2855 Toll Free Telephone
(214) 583-2233 Local Phone Number
(214) 583-2234 Fax Number
hlindley@goldfarbllp.com
www.goldfarbllp.com
SOURCE Goldfarb LLP